Search results for " Recurrence"

showing 10 items of 534 documents

Reconstruction with a pectoralis major myocutaneous flap after left first rib and clavicular chest wall resection for a metastasis from laryngeal can…

2016

We presented a case of recurrent metastasis from epidermoid cancer that occurred in the left clavicle of a patient with a history of laryngeal cancer treated on April 2005 with extended hemilaryngectomy, neck dissection and chemoradiation therapy. On September 2008, he developed a left clavicular metastasis. The disease was initially well controlled by chemoradiotherapy but it recurred 17 months later. The optimal treatment plan was established by several multidisciplinary meetings and the patient subsequently underwent an en bloc resection of the left clavicle, first rib and all the other involved structures. Coverage of the thoracic defect was achieved using pectoralis major myocutaneous …

MalePulmonary and Respiratory Medicinemedicine.medical_specialtymedicine.medical_treatmentSettore MED/21 - Chirurgia ToracicaBone NeoplasmsRibsClavicular resection030204 cardiovascular system & hematologyMetastasisHemilaryngectomy03 medical and health sciences0302 clinical medicineChest wall involvementLaryngeal cancermedicineHumansThoracoplastyNeoplasm MetastasisThoracic WallLaryngeal NeoplasmsRib cagebusiness.industryBone metastasisCancerNeck dissectionGeneral MedicineMiddle AgedPlastic Surgery ProceduresMuscle flapmedicine.diseaseClavicleMyocutaneous FlapSurgerySettore MED/18 - Chirurgia GeneraleCardiothoracic surgeryChest wall involvement; Chest wall reconstruction; Clavicular resection; Laryngeal cancer; Muscle flap; Surgery; Pulmonary and Respiratory Medicine; Cardiology and Cardiovascular MedicineCarcinoma Squamous CellSurgeryNeoplasm Recurrence LocalbusinessChest wall reconstructionCardiology and Cardiovascular Medicine030217 neurology & neurosurgeryChemoradiotherapy
researchProduct

Preliminary experience on safety of regorafenib after sorafenib failure in recurrent hepatocellular carcinoma after liver transplantation

2019

Regorafenib is one option for second-line treatment of hepatocellular carcinoma (HCC), improving overall survival (OS) of sorafenib-tolerant patients who develop progression. We aim to evaluate the safety and outcomes of regorafenib as second-line treatment for HCC recurrence after liver transplantation (LT). This is a retrospective, multicenter, international study including regorafenib-treated LT patients (2015-2018), with analysis of baseline characteristics and evolutionary events during sorafenib/regorafenib treatment. Twenty-eight LT patients (57 years, 7% cirrhotics, 54% performance status 1) were included. Median time from LT to regorafenib initiation was 3.9 (1.1-18.5) years; media…

MalePyridinesmedicine.medical_treatment030230 surgeryLiver transplantationchemotherapyGastroenterologychemistry.chemical_compound0302 clinical medicineAntineoplastic Combined Chemotherapy ProtocolsImmunology and AllergyPharmacology (medical)Liver NeoplasmsMiddle AgedSorafenibPrognosisRecurrent Hepatocellular Carcinomaside effectsHepatocellular carcinomaFemalemedicine.drugSorafenibAdultmedicine.medical_specialtyCarcinoma Hepatocellularcancer/malignancy/neoplasiaclinical research/practice03 medical and health sciencesYoung AdultInternal medicineRegorafenibmedicineHumansAdverse effectAgedRetrospective StudiesTransplantationdrug interactionPerformance statusbusiness.industryPhenylurea Compoundsmedicine.diseaseDiscontinuationLiver TransplantationchemistryDrug Resistance NeoplasmNeoplasm Recurrence Localpharmacologybusinessliver transplantation/hepatologyFollow-Up Studies
researchProduct

Salvage reirradiation for locoregional failure after radiation therapy for prostate cancer: Who, when, where and how?

2014

Even in the current era of dose-escalated radiotherapy for prostate cancer, biochemical recurrence is not uncommon. Furthermore, biochemical failure is not specific to the site of recurrence. One of the major challenges in the management of prostate cancer patients with biochemical failure after radiotherapy is the early discrimination between those with locoregional recurrence only and those with metastatic disease. While the latter are generally considered incurable, patients with locoregional disease may benefit from emerging treatment options. Ultimately, the objective of salvage therapy is to control disease while ensuring minimal collateral damage, thereby optimizing both cancer and t…

MaleQuality ControlOncologyBiochemical recurrencemedicine.medical_specialtyAntineoplastic Agents Hormonalmedicine.medical_treatmentBrachytherapyBrachytherapySalvage therapyBone Neoplasms[SDV.IB.MN]Life Sciences [q-bio]/Bioengineering/Nuclear medicineAdenocarcinomaRadiosurgeryMultimodal Imaging[ SDV.IB.MN ] Life Sciences [q-bio]/Bioengineering/Nuclear medicineManagement of prostate cancerProstate cancerInternal medicinemedicineHumansMulticenter Studies as TopicRadiology Nuclear Medicine and imagingComputingMilieux_MISCELLANEOUSProstatectomySalvage TherapyLymphatic Irradiationbusiness.industryPalliative CareProstatic NeoplasmsCancerAndrogen AntagonistsRadiotherapy DosageProstate-Specific Antigenmedicine.diseaseCombined Modality Therapy3. Good healthRadiation therapyProstate-specific antigenOncologyLymphatic MetastasisDose Fractionation RadiationRadiotherapy Intensity-ModulatedNeoplasm Recurrence LocalbusinessRadiotherapy Image-Guided
researchProduct

Sonographic appearances of the postoperative testis

2015

Purpose: To describe the sonographic findings observed in the testis in patients who have undergone testicle-sparing surgery and surgical biopsies. Methods: We reviewed the color Doppler sonographic findings from 14 patients after testicular interventions: 2 open biopsy procedures for infertility and 12 testicle-sparing surgical procedures (1 for spontaneous intratesticular hemorrhage and 11 for small tumors). Ten patients had benign tumors; one had a malignancy. Three patients were symptomatic; all others were studied as follow-up. Results: Hypoechoic and hypovascular lesions at site of surgery were seen in 10 of the 11 patients after tumorectomy; no changes were observed in one patient. T…

MaleRadiology Nuclear Medicine and ImagingTesticle-sparing surgeryFollow-Up StudieTesticular NeoplasmsRetrospective StudieNuclear Medicine and ImagingTestisHumansTesticular NeoplasmFollow-up; Postoperative changes; Testicle-sparing surgery; Testicular biopsy; Ultrasonography; Radiology Nuclear Medicine and ImagingTesticular biopsyFollow-up; Postoperative changes; Testicle-sparing surgery; Testicular biopsy; Ultrasonography; Follow-Up Studies; Humans; Infertility; Male; Neoplasm Recurrence Local; Retrospective Studies; Testicular Neoplasms; Testis; Ultrasonography; Radiology Nuclear Medicine and ImagingRetrospective StudiesUltrasonographyFollow-upNeoplasm RecurrenceTestiLocalInfertilityPostoperative changeNeoplasm Recurrence LocalRadiologyPostoperative changesHumanFollow-Up Studies
researchProduct

Transanal endoscopic microsurgical excision of pT2 rectal cancer: results and possible indications.

2007

In previous studies, local excision was predominantly established for "low-risk" pT1 rectal cancer. The results obtained with T2 tumors are unclear; recurrence rates of 0 to 67 percent were reported. This study was designed to determine the value of local excision for T2 rectal carcinomas, prognostic factors, and the need for reoperation.After local excision of 649 patients with rectal tumors, pT2 carcinoma was found in 44 patients. In general, immediate reoperation was recommended; however, 24 patients declined further surgery or were not reoperated because of comorbidities. The results were analyzed separately for local R0 resection of low-risk carcinomas and for prognostically unfavorabl…

MaleReoperationmedicine.medical_specialtyMicrosurgeryColorectal cancermedicine.medical_treatmentAnal CanalProctoscopySurgical oncologyRisk FactorsmedicineCarcinomaHumansRadical surgeryAgedAged 80 and overmedicine.diagnostic_testbusiness.industryRectal NeoplasmsGastroenterologyGeneral MedicineMicrosurgeryMiddle Agedmedicine.diseasePrognosisColorectal surgerySurgeryEndoscopyProctoscopyTreatment OutcomeFemaleNeoplasm Recurrence LocalbusinessDiseases of the colon and rectum
researchProduct

What is the Meaning of an Early Anastomotic Recurrence after Curative Right Hemicolectomy? A Synchronous, Metachronous, or What Else?

2019

In this paper we present a case of unexpected early local recurrence after surgery for colon cancer. Notably, an anastomotic recurrence was diagnosed two months after curative right hemicolectomy. Accurate preoperative endoscopic and radiological explorations were carried out, the resection was performed according to the oncological surgical principles, and the pathologic report confirmed the oncological radicality of the treatment performed. Therefore, the precocity of local recurrence appeared surprising, and led us to carry out a review of the literature in order to look into its possible explanations. The results of this research are presented.

MaleReoperationmedicine.medical_specialtyTime Factorsbusiness.industryGeneral surgeryAnastomosis SurgicalColonoscopyGeneral MedicineMiddle AgedAnastomosisSettore MED/18 - Chirurgia GeneraleColorectal Neoplasms.medicineHumansMeaning (existential)Neoplasm Recurrence LocalColorectal NeoplasmsTomography X-Ray ComputedbusinessRight hemicolectomyColectomyFollow-Up StudiesThe American Surgeon
researchProduct

Multicentre propensity score-matched analysis of conventional versus extended abdominoperineal excision for low rectal cancer

2014

Abstract Background Abdominal perineal excision (APE) was originally described with levator ani removal for rectal cancer. An even wider, more aggressive extralevator resection for APE has been proposed. Although some surgeons are performing a very wide ‘extralevator APE (ELAPE)’, there are few data to recommend it routinely. This multicentre study aimed to compare outcomes of APE and ELAPE. Methods A multicentre propensity case-matched analysis comparing two surgical approaches (APE and ELAPE) was performed. All patients who underwent abdominoperineal resection of a rectal tumour were considered for the analysis. Tumour height was defined by magnetic resonance imaging measurement and patie…

MaleReoperationmedicine.medical_specialtymedicine.medical_treatmentPerforation (oil well)Anal CanalPerineumPostoperative ComplicationsmedicineHumansStage (cooking)Propensity ScoreNeoadjuvant therapyAgedRectal Neoplasmsbusiness.industryAbdominoperineal resectionPostoperative complicationMiddle AgedAnal canalTumor BurdenPerineumSurgerymedicine.anatomical_structureCase-Control StudiesPropensity score matchingFemaleSurgeryNeoplasm Recurrence LocalbusinessBritish Journal of Surgery
researchProduct

Dabigatran after Short Heparin Anticoagulation for Acute Intermediate-Risk Pulmonary Embolism: Rationale and Design of the Single-Arm PEITHO-2 Study

2017

AbstractPatients with intermediate-risk pulmonary embolism (PE) may, depending on the method and cut-off values used for definition, account for up to 60% of all patients with PE and have an 8% or higher risk of short-term adverse outcome. Although four non-vitamin K-dependent direct oral anticoagulants (NOACs) have been approved for the treatment of venous thromboembolism, their safety and efficacy as well as the optimal anticoagulation regimen using these drugs have not been systematically investigated in intermediate-risk PE. Moreover, it remains unknown how many patients with intermediate-high-risk and intermediate-low-risk PE were included in most of the phase III NOAC trials. The ongo…

MaleRiskmedicine.medical_specialtypulmonary embolismDrug-Related Side Effects and Adverse Reactionsmedicine.medical_treatmentHemorrhageintermediate risk030204 cardiovascular system & hematologyDabigatran03 medical and health sciencesYoung Adult0302 clinical medicineRecurrenceInternal medicineGermanymedicineHumansdabigatran030212 general & internal medicineProspective StudiesProspective cohort studySurvival analysisvenous thromboembolism recurrencebusiness.industryHeparinAnticoagulantsHematologyThrombolysisHeparinReference Standardsmedicine.diseaseThrombosisSurvival Analysis3. Good healthPulmonary embolismright ventricular functionRegimenTreatment OutcomeResearch Designmajor bleedingAcute Diseasedabigatran; intermediate risk; major bleeding; pulmonary embolism; right ventricular function; venous thromboembolism recurrenceFemalebusinessmedicine.drugFollow-Up Studies
researchProduct

Comparison of two doses of intravenous temsirolimus in patients with relapsed/refractory mantle cell lymphoma

2018

Temsirolimus 175 mg once-weekly for 3 weeks, followed by 75 mg once-weekly intravenously dosed (175/75 mg) is approved in the European Union for treatment of relapsed/refractory mantle cell lymphoma (MCL). A phase IV study explored whether similar efficacy, but improved safety could be achieved with 75 mg without 175 mg loading doses (ClinicaTrials.gov: NCT01180049). Patients with relapsed/refractory MCL were randomized to once-weekly temsirolimus 175/75 mg (n = 47) or 75 mg (n = 42). Treatment continued until objective disease progression. Primary endpoint: progression-free survival (PFS). Secondary endpoints included overall survival (OS) and adverse events (AEs). Median PFS was 4.3 versu…

MaleTemsirolimusCancer ResearchLymphomaDrug ResistanceLymphoma Mantle-CellGastroenterology0302 clinical medicineAntineoplastic Combined Chemotherapy Protocols80 and overClinical endpointmedia_commonAged 80 and overHazard ratioHematologyMiddle AgedPrognosisTemsirolimusSurvival RateLocalOncology030220 oncology & carcinogenesisInjections IntravenousRefractory Mantle Cell LymphomaFemaleIntravenousmedicine.drugsafetymedicine.medical_specialtyoverall survivalmantle cell lymphomaAntineoplastic AgentsDrug Administration ScheduleInjections03 medical and health sciencesRefractoryInternal medicinemedicineHumansmedia_common.cataloged_instanceProgression-free survivalEuropean unionAgedSirolimusSalvage Therapybusiness.industryMantle-Cellmedicine.diseaseSurgeryNeoplasm RecurrenceDrug Resistance NeoplasmNeoplasmMantle cell lymphomaNeoplasm Recurrence Localbusinessprogression-free survivalFollow-Up Studies030215 immunology
researchProduct

Orthokeratinized odontogenic cysts: a Spanish tertiary care centre study based on HPV DNA detection

2018

Abstract Background The role of human papillomavirus (HPV) in orthokeratinized odontogenic cysts (OOCs) has rarely been studied. The objective is to describe the clinicopathological findings in a series of OOCs from a Spanish population that were investigated in relation to the possible presence of HPV. Methods A clinicopathological retrospective analysis followed by a molecular analysis of 28 high- and low-risk HPV genotypes was performed in OOC samples of patients seen during the last 15-years in a Spanish tertiary care center. Results Of 115 odontogenic cysts with keratinization, 16 cases of OOCs were confirmed and evaluated. OOCs occurred predominantly in the mandible of males (mean age…

MaleTertiary careCohort StudiesTertiary Care Centers0302 clinical medicineRecurrenceMedicinePapillomaviridaeBiopsy Needlevirus diseasesMiddle AgedImmunohistochemistryfemale genital diseases and pregnancy complicationsOdontogenicMolecular analysisHPV DNA detectionCell Transformation Neoplastic030220 oncology & carcinogenesisCarcinoma Squamous CellOral and maxillofacial surgeryMouth NeoplasmsAdultmedicine.medical_specialtyHPVAdolescentlcsh:Specialties of internal medicineDents MalaltiesRisk AssessmentYoung Adult03 medical and health scienceslcsh:RC581-951HumansMandibular DiseasesNeoplastic transformationGeneral DentistryRetrospective Studiesbusiness.industryOrthokeratinized odontogenic cystResearch030206 dentistryHigh- and low-riskDermatologyOtorhinolaryngologyOtorhinolaryngologySpainDNA ViralOdontogenic CystsEtiologyNeurology (clinical)HPV High- and low-risk Orthokeratinized odontogenic cyst RecurrencebusinessFollow-Up StudiesHead & Face Medicine
researchProduct